177 related articles for article (PubMed ID: 25267665)
1. Beneficial effect of oral tigecycline treatment on Clostridium difficile infection in gnotobiotic piglets.
Kim HB; Zhang Q; Sun X; Beamer G; Wang Y; Tzipori S
Antimicrob Agents Chemother; 2014 Dec; 58(12):7560-4. PubMed ID: 25267665
[TBL] [Abstract][Full Text] [Related]
2. MBX-500 is effective for treatment of Clostridium difficile infection in gnotobiotic piglets.
Steele J; Zhang Q; Beamer G; Butler M; Bowlin T; Tzipori S
Antimicrob Agents Chemother; 2013 Aug; 57(8):4039-41. PubMed ID: 23689716
[TBL] [Abstract][Full Text] [Related]
3. Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production.
Jump RL; Li Y; Pultz MJ; Kypriotakis G; Donskey CJ
Antimicrob Agents Chemother; 2011 Feb; 55(2):546-9. PubMed ID: 21135181
[TBL] [Abstract][Full Text] [Related]
4. Effects of tigecycline and vancomycin administration on established Clostridium difficile infection.
Theriot CM; Schumacher CA; Bassis CM; Seekatz AM; Young VB
Antimicrob Agents Chemother; 2015 Mar; 59(3):1596-604. PubMed ID: 25547352
[TBL] [Abstract][Full Text] [Related]
5. Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection.
Bossé D; Lemire C; Ruel J; Cantin AM; Ménard F; Valiquette L
Infection; 2013 Apr; 41(2):579-82. PubMed ID: 22996384
[TBL] [Abstract][Full Text] [Related]
6. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.
Baines SD; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2006 Nov; 58(5):1062-5. PubMed ID: 17030519
[TBL] [Abstract][Full Text] [Related]
7. Tigecycline for the treatment of severe Clostridium difficile infection.
Larson KC; Belliveau PP; Spooner LM
Ann Pharmacother; 2011 Jul; 45(7-8):1005-10. PubMed ID: 21730279
[TBL] [Abstract][Full Text] [Related]
8. Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection.
Bassis CM; Theriot CM; Young VB
Antimicrob Agents Chemother; 2014 May; 58(5):2767-74. PubMed ID: 24590475
[TBL] [Abstract][Full Text] [Related]
9. Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile.
Aldape MJ; Heeney DD; Bryant AE; Stevens DL
J Antimicrob Chemother; 2015 Jan; 70(1):153-9. PubMed ID: 25151204
[TBL] [Abstract][Full Text] [Related]
10. Intravenous tigecycline in the treatment of severe recurrent Clostridium difficile colitis.
Cheong EY; Gottlieb T
Med J Aust; 2011 Apr; 194(7):374-5. PubMed ID: 21470094
[No Abstract] [Full Text] [Related]
11. The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study.
Manea E; Sojo-Dorado J; Jipa RE; Benea SN; Rodríguez-Baño J; Hristea A
Clin Microbiol Infect; 2018 Feb; 24(2):180-184. PubMed ID: 28642147
[TBL] [Abstract][Full Text] [Related]
12. Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study.
Gergely Szabo B; Kadar B; Szidonia Lenart K; Dezsenyi B; Kunovszki P; Fried K; Kamotsay K; Nikolova R; Prinz G
Clin Microbiol Infect; 2016 Dec; 22(12):990-995. PubMed ID: 27599690
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.
Kumar M; Mathur T; Barman TK; Ramkumar G; Bhati A; Shukla G; Kalia V; Pandya M; Raj VS; Upadhyay DJ; Vaishnavi C; Chakrabarti A; Das B; Bhatnagar PK
Antimicrob Agents Chemother; 2012 Nov; 56(11):5986-9. PubMed ID: 22869573
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility of Brazilian Clostridium difficile strains determined by agar dilution and disk diffusion.
Fraga EG; Nicodemo AC; Sampaio JL
Braz J Infect Dis; 2016; 20(5):476-81. PubMed ID: 27542867
[TBL] [Abstract][Full Text] [Related]
15. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection.
Herpers BL; Vlaminckx B; Burkhardt O; Blom H; Biemond-Moeniralam HS; Hornef M; Welte T; Kuijper EJ
Clin Infect Dis; 2009 Jun; 48(12):1732-5. PubMed ID: 19435431
[TBL] [Abstract][Full Text] [Related]
16. Evidence for low risk of Clostridium difficile infection associated with tigecycline.
Wilcox MH
Clin Microbiol Infect; 2007 Oct; 13(10):949-52. PubMed ID: 17697004
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
[TBL] [Abstract][Full Text] [Related]
18. Failure of tigecycline to treat severe Clostridium difficile infection.
Kopterides P; Papageorgiou C; Antoniadou A; Papadomichelakis E; Tsangaris I; Dimopoulou I; Armaganidis A
Anaesth Intensive Care; 2010 Jul; 38(4):755-8. PubMed ID: 20715744
[TBL] [Abstract][Full Text] [Related]
19. MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.
Butler MM; Shinabarger DL; Citron DM; Kelly CP; Dvoskin S; Wright GE; Feng H; Tzipori S; Bowlin TL
Antimicrob Agents Chemother; 2012 Sep; 56(9):4786-92. PubMed ID: 22733075
[TBL] [Abstract][Full Text] [Related]
20. Activity of tigecycline against recent European clinical isolates of Clostridium difficile.
Hawser SP
Int J Antimicrob Agents; 2010 Jan; 35(1):97-8. PubMed ID: 19892528
[No Abstract] [Full Text] [Related]
[Next] [New Search]
